$JSPR
Jasper Therapeutics, Inc. Stock $jspr

$jspr Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-K Financial Statement

#000121390023018542 Filed on March 08, 2023

Income Statement

Concept	2022 Q4	2022	2021
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.465M	$16.57M	$11.41M
YoY Change	30.36%	45.19%	137.75%
% of Gross Profit
Research & Development	$9.282M	$34.63M	$25.42M
YoY Change	7.22%	36.21%	60.05%
% of Gross Profit
Depreciation & Amortization	$273.0K	$975.0K	$377.0K
YoY Change	40.72%	158.62%
% of Gross Profit
Operating Expenses	$13.75M	$51.20M	$36.83M
YoY Change	13.78%	38.99%	78.08%
Operating Profit		-$51.20M	-$36.83M
YoY Change		38.99%
Interest Expense	$0.00	$0.00	-$3.501M
YoY Change	-100.0%	-100.0%	-68.13%
% of Operating Profit
Other Income/Expense, Net	$536.0K	$586.0K	$9.697M
YoY Change	-82.26%	-93.96%
Pretax Income	-$13.21M	-$37.69M	-$30.64M
YoY Change	45.87%	23.0%	-3.26%
Income Tax
% Of Pretax Income
Net Earnings	-$13.21M	-$37.69M	-$30.64M
YoY Change	45.87%	23.0%	-3.26%
Net Earnings / Revenue
Basic Earnings Per Share		-$1.03	-$2.69
Diluted Earnings Per Share	-$0.31	-$1.03	-$809.3K
COMMON SHARES
Basic Shares Outstanding		36.48M shares	11.39M shares
Diluted Shares Outstanding		36.48M shares	11.39M shares

Balance Sheet

Concept	2022 Q4	2022	2021
SHORT-TERM ASSETS
Cash & Short-Term Investments	$38.25M	$38.25M	$84.70M
YoY Change	-54.84%	-54.84%	326.96%
Cash & Equivalents	$38.25M	$38.25M	$84.70M
Short-Term Investments
Other Short-Term Assets	$246.0K	$2.568M	$2.432M
YoY Change	1071.43%	5.59%	884.62%
Inventory
Prepaid Expenses
Receivables
Other Receivables	$118.0K
Total Short-Term Assets	$41.73M	$41.73M	$87.83M
YoY Change	-52.49%	-52.49%	324.61%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.568M	$5.454M	$4.833M
YoY Change	-3.2%	12.85%	138.2%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$759.0K	$1.176M	$990.0K
YoY Change	17.67%	18.79%	53.97%
Total Long-Term Assets	$6.630M	$6.630M	$5.823M
YoY Change	13.86%	13.86%	117.93%
TOTAL ASSETS
Total Short-Term Assets	$41.73M	$41.73M	$87.83M
Total Long-Term Assets	$6.630M	$6.630M	$5.823M
Total Assets	$48.36M	$48.36M	$93.65M
YoY Change	-48.36%	-48.36%	300.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.768M	$1.768M	$3.919M
YoY Change	-54.89%	-54.89%	176.57%
Accrued Expenses	$5.103M	$5.103M	$4.101M
YoY Change	45.14%	24.43%	61.71%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$7.065M	$7.065M	$8.020M
YoY Change	-11.91%	-11.91%	99.9%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.353M	$5.307M	$16.12M
YoY Change	265.94%	-67.07%	51.54%
Total Long-Term Liabilities	$2.353M	$5.307M	$16.12M
YoY Change	265.94%	-67.07%	51.54%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.065M	$7.065M	$8.020M
Total Long-Term Liabilities	$2.353M	$5.307M	$16.12M
Total Liabilities	$12.37M	$12.37M	$24.14M
YoY Change	-48.74%	-48.74%	64.78%
SHAREHOLDERS EQUITY
Retained Earnings	-$105.1M
YoY Change	55.87%
Common Stock	$4.000K
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$35.99M	$35.99M	$69.52M
YoY Change
Total Liabilities & Shareholders Equity	$48.36M	$48.36M	$93.65M
YoY Change	-48.36%	-48.36%	300.97%

Cashflow Statement

Concept	2022 Q4	2022	2021
OPERATING ACTIVITIES
Net Income	-$13.21M	-$37.69M	-$30.64M
YoY Change	45.87%	23.0%	-3.26%
Depreciation, Depletion And Amortization	$273.0K	$975.0K	$377.0K
YoY Change	40.72%	158.62%
Cash From Operating Activities	-$12.65M	-$45.86M	-$33.68M
YoY Change	-13.29%	36.17%	84.37%
INVESTING ACTIVITIES
Capital Expenditures	$82.00K	$576.0K	-$2.428M
YoY Change	-111.53%	-123.72%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$82.00K	-$576.0K	-$2.428M
YoY Change	-88.47%	-76.28%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$28.00K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	28.00K	$55.00K	101.0M
YoY Change	-103.08%	-99.95%	794.56%
NET CHANGE
Cash From Operating Activities	-12.65M	-$45.86M	-33.68M
Cash From Investing Activities	-82.00K	-$576.0K	-2.428M
Cash From Financing Activities	28.00K	$55.00K	101.0M
Net Change In Cash	-12.70M	-$46.38M	64.86M
YoY Change	-21.62%	-171.5%
FREE CASH FLOW
Cash From Operating Activities	-$12.65M	-$45.86M	-$33.68M
Capital Expenditures	$82.00K	$576.0K	-$2.428M
Free Cash Flow	-$12.73M	-$46.43M	-$31.25M
YoY Change	-8.25%	48.59%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-39138
CY2022	dei	Entity Registrant Name EntityRegistrantName	JASPER THERAPEUTICS, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-2984849
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	2200 Bridge Pkwy
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite #102
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Redwood City
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94065
CY2022	dei	City Area Code CityAreaCode	(650)
CY2022	dei	Local Phone Number LocalPhoneNumber	549-1400
CY2022	dei	Security12b Title Security12bTitle	Voting Common Stock, par value $0.0001 per share
CY2022	dei	Trading Symbol TradingSymbol	JSPR
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	48700000	usd
CY2022	dei	Auditor Firm AuditorFirmId	238
CY2022	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2022	dei	Auditor Location AuditorLocation	San Jose, California
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38250000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	84701000	usd
CY2022Q4	us-gaap	Other Receivables OtherReceivables	663000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2818000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3130000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	41731000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	87831000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3568000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3686000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1886000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1147000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	417000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	345000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	759000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	645000	usd
CY2022Q4	us-gaap	Assets Assets	48361000	usd
CY2021Q4	us-gaap	Assets Assets	93654000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1768000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3919000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	865000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	505000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	4432000	usd
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	3596000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7065000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8020000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2786000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2380000	usd
CY2022Q4	jspr	Common Stock Warrant Liability CommonStockWarrantLiability	150000	usd
CY2021Q4	jspr	Common Stock Warrant Liability CommonStockWarrantLiability	7350000	usd
CY2022Q4	jspr	Earnout Liability EarnoutLiability	18000	usd
CY2021Q4	jspr	Earnout Liability EarnoutLiability	5743000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2353000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	643000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	12372000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	24136000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	492000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	492000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38045677	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38045677	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37855114	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37855114	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	141120000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	136964000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-105135000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-67450000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	35989000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	69518000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	48361000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	93654000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	34627000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25421000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16569000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11412000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	51196000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	36833000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-51196000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-36833000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-7200000	usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-500000	usd
CY2022	jspr	Change In Fair Value Of Earnout Liability ChangeInFairValueOfEarnoutLiability	-5725000	usd
CY2021	jspr	Change In Fair Value Of Earnout Liability ChangeInFairValueOfEarnoutLiability	-9277000	usd
CY2021	jspr	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	3501000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	586000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-80000	usd
CY2022	us-gaap	Other Income OtherIncome	13511000	usd
CY2021	us-gaap	Other Income OtherIncome	6196000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-37685000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-30637000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.03
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.69
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36482761	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11393753	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-35130000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	235000	usd
CY2021	jspr	Issuance Of Common Stock Upon Exercise Of Common Stock Warrants IssuanceOfCommonStockUponExerciseOfCommonStockWarrants	1000	usd
CY2021	jspr	Conversion Of Redeemable Convertible Preferred Stock Into Common Stock In Connection With The R ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithTheR	66249000	usd
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	67742000	usd
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	10000	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1048000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-30637000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	69518000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	27000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	28000	usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	10000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	4091000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-37685000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	35989000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-37685000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-30637000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	975000	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	377000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	335000	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	189000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	4091000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	1048000	usd
CY2021	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	3501000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-7200000	usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-500000	usd
CY2022	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	5725000	usd
CY2021	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	9277000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-312000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	2212000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets	663000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets	-600000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	114000	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	347000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2151000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2938000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	836000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	959000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-589000	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-117000	usd
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	1720000	usd
CY2021	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-200000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-45858000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-33678000	usd
CY2022	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	576000	usd
CY2021	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	2428000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-576000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2428000	usd
CY2021	us-gaap	Proceeds From Hedge Financing Activities ProceedsFromHedgeFinancingActivities	95271000	usd
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	5288000	usd
CY2021	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	10750000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	27000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	235000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	28000	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	55000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	100969000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-46379000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	64863000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	85046000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20183000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38667000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	85046000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1074000	usd
CY2022	jspr	Noncash Leasehold Improvements NoncashLeaseholdImprovements	-281000	usd
CY2021	jspr	Noncash Leasehold Improvements NoncashLeaseholdImprovements	1378000	usd
CY2022	jspr	Vesting Of Founders Restricted Stock VestingOfFoundersRestrictedStock	10000	usd
CY2021	jspr	Vesting Of Founders Restricted Stock VestingOfFoundersRestrictedStock	10000	usd
CY2021	jspr	Conversion Of Redeemable Convertible Preferred Stock Into Common Stock In Connection With Reve ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithReve	-66249000	usd
CY2021	jspr	Deferred Issuance Costs Reclassified To Additional Paid In Capital DeferredIssuanceCostsReclassifiedToAdditionalPaidInCapital	5288000	usd
CY2021	jspr	Net Liabilities Assumed Upon The Closing Of Reversed Recapitalization NetLiabilitiesAssumedUponTheClosingOfReversedRecapitalization	-7222000	usd
CY2021	jspr	Recognition Of Earnout Liability RecognitionOfEarnoutLiability	15020000	usd
CY2021	jspr	Recognitionsettlement Of Derivatives Tranche Liability RecognitionsettlementOfDerivativesTrancheLiability	-11659000	usd
CY2022	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	72000	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 1. ORGANIZATION AND DESCRIPTION OF BUSINESS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Description of Business </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Jasper Therapeutics, Inc. (“Jasper” or the “Company”), formerly known as Amplitude Healthcare Acquisition Corporation (“AMHC”), is a clinical-stage biotechnology company dedicated to enabling cures through therapeutics targeting mast and hemopoietic stem cells. The Company is focused on the development and commercialization of safer <span style="background-color: white">and</span> more effective therapeutic agents for diseases such as Chronic Spontaneous Urticaria, Lower to Intermediate Risk Myelodysplastic Syndrome and novel conditioning regimens for stem cell transplantation and <span style="background-color: white">ex-vivo</span> gene <span style="background-color: white">therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. </span>The Company is headquartered in Redwood City, California.</span> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">On September 24, 2021 (the “Closing Date”), the Company consummated the previously announced business combination (the “Business Combination” or “Reverse Recapitalization” for accounting purposes) pursuant to the terms of the Business Combination Agreement, dated as of May 5, 2021 (the “BCA”), by and among AMHC, Ample Merger Sub, Inc., a then-wholly-owned subsidiary of AMHC (“Merger Sub”), and the pre-Business Combination Jasper Therapeutics, Inc. (now named Jasper Tx Corp.) (“Old Jasper”). Pursuant to the terms of the BCA, on the Closing Date, (i) Merger Sub merged with and into Old Jasper, with Old Jasper as the surviving company in the Business Combination, and, after giving effect to such Business Combination, Old Jasper became a wholly-owned subsidiary of AMHC and changed its name to “Jasper Tx Corp.”, and (ii) AMHC changed its name to “Jasper Therapeutics, Inc.”.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">In addition, concurrently with the execution of the BCA, certain investors (“PIPE Investors”) entered into Subscription Agreements with AMHC whereby such investors subscribed for the purchase of an aggregate of 10,000,000 shares of AMHC’s Class A Common Stock at a price of $10.00 per share for aggregate gross proceeds of $100.0 million (“PIPE Financing”). The PIPE Financing was consummated concurrently with the closing of the Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">Please refer to Note 3, “Reverse Recapitalization”, for further details of the Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Liquidity and <span style="background-color: white">Going Concern</span></i></b> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">The Company has incurred significant losses and negative cash flows from operations since its inception. During the years ended December 31, 2022 and 2021, the Company incurred net losses of $37.7 million and $30.6 million, respectively. During the years ended December 31, 2022 and 2021, the Company had negative operating cash flows of $45.9 million and $33.7 million, respectively. As of December 31, 2022, the Company had an accumulated deficit of $105.1 million. The Company expects to continue to incur substantial losses, and its ability to achieve and sustain profitability will depend on the successful development, approval, and commercialization of product candidates and on the achievement of sufficient revenues to support the Company’s cost structure.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of December 31, 2022, the Company had cash and cash equivalents of $38.3 million. The Company’s management expects that the existing cash and cash equivalents, together with the total estimated net proceeds of $101.4 million from the public offering that closed in January 2023 and the sale of shares of common stock pursuant to the ATM Prospectus Supplement in January 2023, will be sufficient to fund the Company’s operating plans for at least twelve months from the issuance date of these consolidated financial statements. Therefore, based on management’s updated evaluation of the Company’s ability to continue as a going concern, management has concluded the factors that previously raised substantial doubt about the Company’s ability to continue as a going concern no longer exist as of the issuance date of these consolidated financial statements. However, the Company will need to raise additional financing to continue its products’ development for the foreseeable future, and will continue to need to do so until it becomes profitable. The Company’s management plans to monitor expenses and raise additional capital through a combination of public and private equity, debt financings, strategic alliances, and licensing arrangements. The Company’s ability to access capital when needed is not assured and, if capital is not available to the Company when, and in the amounts needed, the Company may be required to significantly curtail, delay or discontinue one or more of its research or development programs or the commercialization of any product candidate, or be unable to expand its operations or otherwise capitalize on the Company’s business opportunities, as desired, which could materially harm the Company’s business, financial condition and results of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">The consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The consolidated financial statements do not reflect any adjustments relating to the recoverability and reclassifications of assets and liabilities that might be necessary if the Company is unable to continue as a going concern.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Coronavirus Pandemic</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">While conditions related to the COVID-19 pandemic improved in 2022 compared to 2021, the pandemic continues to be dynamic, and near-term challenges across the economy remain. While the Company’s operations to date have not been significantly impacted by the <span style="background-color: white">continuing </span>COVID-19 pandemic, it cannot at this time predict the specific extent, duration, or full impact that the COVID-19 pandemic will have on its business, financial condition and operations, as the ongoing effects of COVID-19 remain difficult to predict due to numerous uncertainties, including the severity, duration and resurgence of the outbreak, new variants and the contagiousness of these new variants, the effectiveness of health and safety measures, including vaccines and therapies, government and community responses, the pace and strength of the economic recovery, supply chain pressures, and potential delays in enrollment in clinical trials, among others. The impact of the COVID-19 pandemic on the Company’s financial performance will depend on future developments, including the duration and spread of the pandemic, its impact on the Company’s clinical trial enrollment, trial sites, contract research organizations (“CROs”), contract manufacturing organizations (“CMOs”), and other third parties with whom it does business, its impact on regulatory authorities and the Company’s key scientific and management personnel, progress and effectiveness of vaccinations and related governmental advisories and restrictions. These developments and the impact of the COVID-19 pandemic on the financial markets and the overall economy are highly uncertain and cannot be predicted. The Company will continue to actively monitor the effects of the COVID-19 pandemic and will continue to take appropriate steps to attempt to mitigate the impacts to its employees, business, financial condition and operations.</p>
CY2022	us-gaap	Profit Loss ProfitLoss	37700000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	30600000	usd
CY2022	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	45900000	usd
CY2021	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	33700000	usd
CY2022Q4	us-gaap	Accumulated Capitalized Interest Costs AccumulatedCapitalizedInterestCosts	105100000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	38300000	usd
CY2022	jspr	Aggregate Gross Proceeds AggregateGrossProceeds	101400000	usd
CY2022	us-gaap	Convertible Preferred Stock Terms Of Conversion ConvertiblePreferredStockTermsOfConversion	All historical share data and per-share amounts were retrospectively adjusted to reflect the effect of the exchange ratio of 0.2823780 per one share, which was determined at the closing of the Reverse Recapitalization, except for the 100 shares of Series A-2 redeemable convertible preferred stock.
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions and judgements that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions made in the consolidated financial statements include but are not limited to the valuation of common and redeemable convertible preferred stock before the Reverse Recapitalization, the determination of the incremental borrowing rate used for operating lease liabilities, valuation of derivative liability before the Reverse Recapitalization, valuation of earnout liability and the measurement of stock-based compensation expense. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p>
CY2022Q4	jspr	Common Stock Of Amhc Outstanding Prior To The Business Combination CommonStockOfAMHCOutstandingPriorToTheBusinessCombination	12500000	shares
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	38250000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	84701000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	417000	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	345000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	38667000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	85046000	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Concentrations of Credit Risk and Other Risks and Uncertainties</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">The Company’s cash and cash equivalents are maintained with financial institutions in the United States of America. Management believes that these financial institutions are financially sound. The Company has not experienced any losses on its cash and cash equivalents.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">The Company is subject to risks common to companies in the development stage, including, but not limited to, development and regulatory approval of new product candidates, development of markets and distribution channels, dependence on key personnel, and the ability to obtain additional capital as needed to fund its product plans. To achieve profitable operations, the Company must successfully develop and obtain requisite regulatory approvals for, manufacture, and market its product candidates. There can be no assurance that any such product candidate can be developed and approved or manufactured at an acceptable cost and with appropriate performance characteristics, or that such product will be successfully marketed. These factors could have a material adverse effect on the Company’s future financial results.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">Products developed by the Company require approval from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commercial sales. There can be no assurance that the Company’s future products will receive the necessary clearances. If the Company were denied such clearances or such clearances were delayed, it could have a materially adverse impact on the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p>
CY2022	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	200000	shares
CY2022Q4	jspr	Redemption Of Amhc Shares RedemptionOfAMHCShares	-9262099	shares
CY2022Q4	jspr	Common Stock Shares CommonStockShares	3037901	shares
CY2022Q4	jspr	Shares Issued In Pipe Financing SharesIssuedInPIPEFinancing	10000000	shares
CY2022Q4	jspr	Business Combination And Pipe Financing Shares BusinessCombinationAndPIPEFinancingShares	13037901	shares
CY2022	jspr	Lease Term Year LeaseTermYear	P1Y
CY2022Q4	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	4999863	shares
CY2022Q4	jspr	Common Stocks Shares Issued CommonStocksSharesIssued	1050000	shares
CY2022Q4	jspr	Old Jasper Shares OldJasperShares	24778409	shares
CY2022Q4	jspr	Total Shares Of Common Stock Immediately After The Business Combination TotalSharesOfCommonStockImmediatelyAfterTheBusinessCombination	37816310	shares
CY2022	jspr	Business Combination Descriptions BusinessCombinationDescriptions	In accordance with the BCA, at the closing of the Business Combination, each share of Old Jasper common stock and Old Jasper redeemable convertible preferred stock outstanding immediately prior to the closing was automatically cancelled, extinguished and converted into the number of shares of the Company’s common stock or, in certain circumstances, the Company’s non-voting common stock, based on Old Jasper’s equity value of $275.0 million divided by $10.00. The exchange ratio agreed between the parties was one-for-0.282378 share of the Company’s common stock for all Old Jasper stockholders, except for Amgen Inc. (“Amgen”).
CY2022Q4	jspr	Common Stock Represented CommonStockRepresented	0.08	pure
CY2022	jspr	Received Shares ReceivedShares	1050000	shares
CY2022	jspr	Net Proceeds NetProceeds	95300000	usd
CY2022	jspr	Cash Held In Trust Account CashHeldInTrustAccount	5500000	usd
CY2022	jspr	Cash Received CashReceived	100000000	usd
CY2022	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1200000	usd
CY2022Q4	us-gaap	Business Acquisition Cost Of Acquired Entity Transaction Costs BusinessAcquisitionCostOfAcquiredEntityTransactionCosts	5300000	usd
CY2022Q4	us-gaap	Assets Net AssetsNet	600000	usd
CY2022	jspr	Warrant Liabilities WarrantLiabilities	7900000	usd
CY2022Q4	jspr	Fair Value Earnout Liability FairValueEarnoutLiability	15000000	usd
CY2021Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	2056000	usd
CY2022	us-gaap	Equipment Expense EquipmentExpense	1706000	usd
CY2022Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	37250000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	37250000	usd
CY2022Q4	jspr	Common Stock Warrant Liability CommonStockWarrantLiability	150000	usd
CY2022Q4	us-gaap	Other Liabilities OtherLiabilities	18000	usd
CY2022Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	168000	usd
CY2021Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	83701000	usd
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	83701000	usd
CY2021Q4	jspr	Common Stock Warrant Liability CommonStockWarrantLiability	7350000	usd
CY2021Q4	us-gaap	Other Liabilities OtherLiabilities	5743000	usd
CY2021Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	13093000	usd
CY2021	jspr	Derivative Tranche Liability DerivativeTrancheLiability	3500000	usd
CY2022Q4	jspr	Redeemable Convertible Preferred Stock Value RedeemableConvertiblePreferredStockValue	1.57	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.75
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0	pure
CY2021	us-gaap	Equipment Expense EquipmentExpense	1569000	usd
CY2022Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	502000	usd
CY2022Q4	us-gaap	Derivative Assets Liabilities At Fair Value Net DerivativeAssetsLiabilitiesAtFairValueNet	18	usd
CY2022	jspr	Valuation Methodology ValuationMethodology	Monte Carlo Simulation
CY2022	jspr	Common Stock Price CommonStockPrice	0.48
CY2022	jspr	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm	P1Y8M23D
CY2022	jspr	Expected Volatility ExpectedVolatility	1.05	pure
CY2022	jspr	Riskfree Interest Rate RiskfreeInterestRate	0.044	pure
CY2021Q4	us-gaap	Derivative Assets Liabilities At Fair Value Net DerivativeAssetsLiabilitiesAtFairValueNet	5743	usd
CY2021	jspr	Valuation Methodology ValuationMethodology	Monte Carlo Simulation
CY2021	jspr	Common Stock Price CommonStockPrice	7.85
CY2021	jspr	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm	P2Y8M23D
CY2021	jspr	Expected Volatility ExpectedVolatility	0.74	pure
CY2021	jspr	Riskfree Interest Rate RiskfreeInterestRate	0.009	pure
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1362000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	2074000	usd
CY2022	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	842000	usd
CY2021	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	139000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	250000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	548000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	246000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	219000	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	118000	usd
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	150000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	2818000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	3130000	usd
CY2022Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	2477000	usd
CY2021Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	208000	usd
CY2022Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	145000	usd
CY2021Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	140000	usd
CY2022Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	90000	usd
CY2021Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	90000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4920000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4063000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1352000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	377000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3568000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3686000	usd
CY2022	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	1000000	usd
CY2021	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	400000	usd
CY2022Q4	jspr	Research And Development Accrued Expenses ResearchAndDevelopmentAccruedExpenses	2651000	usd
CY2021Q4	jspr	Research And Development Accrued Expenses ResearchAndDevelopmentAccruedExpenses	1660000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1587000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1151000	usd
CY2021Q4	jspr	License Option Liability Current LicenseOptionLiabilityCurrent	200000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	194000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	585000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	4432000	usd
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	3596000	usd
CY2022Q4	jspr	Derivative Liability DerivativeLiability	2264000	usd
CY2021Q4	jspr	Derivative Liability DerivativeLiability	600000	usd
CY2021Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	24000	usd
CY2022Q4	jspr	Restricted Stock Liabilities RestrictedStockLiabilities	9000	usd
CY2021Q4	jspr	Restricted Stock Liabilities RestrictedStockLiabilities	19000	usd
CY2022Q4	us-gaap	Other Liabilities And Deferred Revenue Noncurrent OtherLiabilitiesAndDeferredRevenueNoncurrent	80000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2353000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	643000	usd
CY2020Q4	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	2300000	usd
CY2022	jspr	Percentage Of Licensing Fees PercentageOfLicensingFees	0.001	pure
CY2022	jspr	Fund Technology FundTechnology	1000000	usd
CY2022	us-gaap	Debt Conversion Converted Instrument Rate DebtConversionConvertedInstrumentRate	0.60	pure
CY2022Q4	us-gaap	Investment Interest Rate InvestmentInterestRate	0.25	pure
CY2021Q1	jspr	Received Aggregate From Cirm ReceivedAggregateFromCIRM	600000	usd
CY2021Q1	jspr	Received Aggregate From Cirm ReceivedAggregateFromCIRM	600000	usd
CY2021Q4	us-gaap	Deferred Long Term Liability Charges DeferredLongTermLiabilityCharges	600000	usd
CY2022Q4	jspr	Other Receivables Milestone OtherReceivablesMilestone	1000000	usd
CY2022Q4	jspr	Other Receivables Milestone OtherReceivablesMilestone	700000	usd
CY2022	jspr	Amount Future Distribution Under Grant Value AmountFutureDistributionUnderGrantValue	50000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	200000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	0	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	200000	usd
CY2022	jspr	Annual License Maintenance Fees Description AnnualLicenseMaintenanceFeesDescription	The Company will pay annual license maintenance fees, beginning on the first anniversary of the effective date of the agreement and ending upon the first commercial sale of a product, method, or service in the licensed field of use, as follows: $25,000 for each first and second year, $35,000 for each third and fourth year, and $50,000 at each anniversary thereafter ending upon the first commercial sale. The Company is also obligated to pay late-stage clinical development milestones and first commercial sales milestone payments of up to $9.0 million in total. The Company will also pay low single-digit royalties on net sales of licensed products, if approved. The Company paid a $25,000 license maintenance fee in March 2022, which was recognized as research and development expense in the statements of operations and comprehensive loss for the year ended December 31, 2022.
CY2022	us-gaap	Derivative Maturity Dates DerivativeMaturityDates	2026-09-24
CY2021Q3	us-gaap	Equity Method Investment Quoted Market Value EquityMethodInvestmentQuotedMarketValue	7900000	usd
CY2022	us-gaap	Gain Loss On Fair Value Hedges Recognized In Earnings GainLossOnFairValueHedgesRecognizedInEarnings	7200000	usd
CY2021	us-gaap	Gain Loss On Fair Value Hedges Recognized In Earnings GainLossOnFairValueHedgesRecognizedInEarnings	500000	usd
CY2022	jspr	Common Stock Warrants Fair Value CommonStockWarrantsFairValue	200000	usd
CY2021	jspr	Common Stock Warrants Fair Value CommonStockWarrantsFairValue	7400000	usd
CY2022	jspr	Contingent Earnout Liabilities Description ContingentEarnoutLiabilitiesDescription	Upon the closing of the Business Combination and pursuant to the Sponsor Support Agreement, the Sponsor agreed to place the Earnout Shares into escrow, which will be released as follows: (a) 250,000 Earnout Shares will be released if, during the period from and after September 24, 2021 until September 24, 2024 (the “Earnout Period”), over any twenty trading days within any thirty-day consecutive trading day period, the volume-weighted average price of the Company’s common stock (the “Applicable VWAP”) is greater than or equal to $11.50, (b) 500,000 Earnout Shares will be released if, during the Earnout Period, the Applicable VWAP is greater than or equal to $15.00, and (c) 300,000 Earnout Shares will be released if, during the Earnout Period, the Applicable VWAP is greater than or equal to $18.00 (the “triggering events”).
CY2020Q3	jspr	Rentable Square Feet With Lease Commencement RentableSquareFeetWithLeaseCommencement	7781	sqm
CY2022Q1	jspr	Rentable Square Feet With Lease Commencement RentableSquareFeetWithLeaseCommencement	5611	sqft
CY2022Q1	jspr	Agreement For Square Feet Of Temporary Office Space AgreementForSquareFeetOfTemporaryOfficeSpace	5144	sqft
CY2022	us-gaap	Payments For Rent PaymentsForRent	100000	usd
CY2022	jspr	Lessor Amount LessorAmount	400000	usd
CY2022	jspr	Improvement Allowance Description ImprovementAllowanceDescription	To complete certain leasehold improvements, the lessor agreed to provide the Company a tenant improvement allowance of $1.5 million as well as an option to take an additional allowance of $0.4 million to be repaid over the lease term at an interest rate of 9% per annum, which the Company exercised.
CY2022Q4	jspr	Leasehold Improvement Gross LeaseholdImprovementGross	300000	usd
CY2021Q4	jspr	Leasehold Improvement Gross LeaseholdImprovementGross	1600000	usd
CY2022	jspr	Net Construction Costs Percentage NetConstructionCostsPercentage	0.05	pure
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	622000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	479000	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	129000	usd
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	326000	usd
CY2022	us-gaap	Lease Cost LeaseCost	751000	usd
CY2021	us-gaap	Lease Cost LeaseCost	805000	usd
CY2022	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	870000	usd
CY2020	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	301000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y7M6D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y7M6D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08	pure
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08	pure
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1119000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1153000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1187000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	740000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4199000	usd
CY2022Q4	us-gaap	Unrecorded Unconditional Purchase Obligation Imputed Interest UnrecordedUnconditionalPurchaseObligationImputedInterest	548000	usd
CY2022Q4	jspr	Operating Leases Liability OperatingLeasesLiability	3651000	usd
CY2022Q4	jspr	Less Current Portion Of Lease Liability LessCurrentPortionOfLeaseLiability	-865000	usd
CY2022Q4	jspr	Noncurrent Portion Of Lease Liability NoncurrentPortionOfLeaseLiability	2786000	usd
CY2020	jspr	Pay Stanford Net PayStanfordNet	900000	usd
CY2020	jspr	Pay Stanford Net Term PayStanfordNetTerm	P3Y
CY2020	jspr	First Milestone Agremment FirstMilestoneAgremment	300000	usd
CY2022Q1	us-gaap	Research And Development Expense Software Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost	300000	usd
CY2021Q1	jspr	License Agreements Description LicenseAgreementsDescription	In March 2021, the Company entered into the Stanford License Agreement (Note 7), pursuant to which the Company is required to pay annual license maintenance fees, beginning on the first anniversary of the effective date of the agreement and ending upon the first commercial sale of a product, method, or service in the licensed field of use, as follows: $25,000 for each first and second year, $35,000 for each third and fourth year, and $50,000 at each anniversary thereafter ending upon the first commercial sale. The Company is also obligated to pay late-stage clinical development milestones and first commercial sales milestone payments of up to $9.0 million in total.
CY2022Q1	us-gaap	Direct Taxes And Licenses Costs DirectTaxesAndLicensesCosts	25000	usd
CY2022Q4	jspr	Common Stock Shares Of Voting CommonStockSharesOfVoting	37134655	shares
CY2021Q4	jspr	Common Stock Shares Of Voting CommonStockSharesOfVoting	36559092	shares
CY2022Q4	jspr	Shares Of Nonvoting Common Stock SharesOfNonvotingCommonStock	911022	shares
CY2021Q4	jspr	Shares Of Nonvoting Common Stock SharesOfNonvotingCommonStock	1296022	shares
CY2021	us-gaap	Restricted Stock Expense RestrictedStockExpense	31000000	usd
CY2022Q4	jspr	Outstanding And Issued Common Stock Option OutstandingAndIssuedCommonStockOption	6169180	shares
CY2021Q4	jspr	Outstanding And Issued Common Stock Option OutstandingAndIssuedCommonStockOption	2660383	shares
CY2022Q4	jspr	Common Stock Warrant CommonStockWarrant	4999863	shares
CY2021Q4	jspr	Common Stock Warrant CommonStockWarrant	4999883	shares
CY2022Q4	us-gaap	Capital Units Outstanding CapitalUnitsOutstanding	2617445	shares
CY2022Q4	jspr	Shares Available For Grant Under2021 Equity Incentive Plan SharesAvailableForGrantUnder2021EquityIncentivePlan	1383661	shares
CY2021Q4	jspr	Shares Available For Grant Under2021 Equity Incentive Plan SharesAvailableForGrantUnder2021EquityIncentivePlan	4422480	shares
CY2022Q4	jspr	Shares Available For Grant Under2019 Equity Incentive Plan SharesAvailableForGrantUnder2019EquityIncentivePlan	1295672	shares
CY2022Q4	jspr	Shares Available For Grant Under2021 Employee Stock Purchase Plan SharesAvailableForGrantUnder2021EmployeeStockPurchasePlan	869117	shares
CY2021Q4	jspr	Shares Available For Grant Under2021 Employee Stock Purchase Plan SharesAvailableForGrantUnder2021EmployeeStockPurchasePlan	550000	shares
CY2022Q4	jspr	Total Shares Of Common Stock Reserved TotalSharesOfCommonStockReserved	17334938	shares
CY2021Q4	jspr	Total Shares Of Common Stock Reserved TotalSharesOfCommonStockReserved	12632746	shares
CY2022Q4	jspr	Common Stock CommonStock	150000000	usd
CY2022Q4	jspr	Aggregate Offering Price AggregateOfferingPrice	15500000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Description ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription	The number of shares available for issuance under the 2021 Plan will increase annually in an amount equal to the least of (i) 2,750,000 shares, (ii) a number of shares equal to 4% of the total number of shares of all classes of common stock of the Company outstanding on the last day of the immediately preceding fiscal year, or (iii) such lesser number of shares determined by the Company’s Board of Directors (the “Board”) no later than the last day of the immediately preceding fiscal year. The number of shares of common stock available for issuance under the ESPP will increase annually in an amount equal to the least of (i) 550,000 shares of common stock, (ii) a number of shares of common stock equal to 1% of the total number of shares of all classes of common stock of the Company on the last day of the immediately preceding fiscal year, or (iii) such number of shares determined by the Board.
CY2022	us-gaap	Stock Dividends Shares StockDividendsShares	4520610	shares
CY2022	jspr	Shares Issued Under Espp SharesIssuedUnderESPP	59434	shares
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	869117	shares
CY2022	jspr	Fair Market Value Of Common Stock Percentage FairMarketValueOfCommonStockPercentage	0.85	pure
CY2022Q4	us-gaap	Reporting Unit Percentage Of Fair Value In Excess Of Carrying Amount ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount	1	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.10	pure
CY2022	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	0	usd
CY2022Q4	jspr	Sharebased Compensation Arrangements By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	100000	usd
CY2021Q4	jspr	Sharebased Compensation Arrangements By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	2100000	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1800000	usd
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1400000	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	2.38
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	2.66
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	6600000	usd
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y8M12D
CY2022	jspr	Performancebased Stock Options PerformancebasedStockOptions	100000	usd
CY2022	jspr	Recognized Over A Weightedaverage Period RecognizedOverAWeightedaveragePeriod	P0Y3M18D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1600000	shares
CY2022	jspr	Description Of Espp DescriptionOfESPP	The Company issued 59,434 shares of common stock under the ESPP as of December 31, 2022 and recognized $0.1 million compensation expense related to the ESPP for the year ended December 31, 2022. Unamortized stock-based compensation for shares issuable under the ESPP as of December 31, 2022 was less than $0.1 million, which is expected to be recognized over a weighted-average period of 0.4 years. The Company recorded less than $0.1 million in accrued expenses and other current liabilities related to contributions withheld as of December 31, 2022.
CY2022	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	1423000	usd
CY2021	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	612000	usd
CY2022	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	2668000	usd
CY2021	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	436000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost	4091000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost	1048000	usd
CY2022	jspr	Stockbased Compensation Expense StockbasedCompensationExpense	200000	usd
CY2021	jspr	Stockbased Compensation Expense StockbasedCompensationExpense	100000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend	0	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-37685000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-30637000	usd
CY2022	us-gaap	Weighted Average Basic Shares Outstanding Pro Forma WeightedAverageBasicSharesOutstandingProForma	37935117	shares
CY2021	us-gaap	Weighted Average Basic Shares Outstanding Pro Forma WeightedAverageBasicSharesOutstandingProForma	12363677	shares
CY2022	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	402356	shares
CY2021	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	685129	shares
CY2022	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	1050000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	284795	shares
CY2022	us-gaap	Weighted Average Number Of Limited Partnership And General Partnership Unit Outstanding Basic And Diluted WeightedAverageNumberOfLimitedPartnershipAndGeneralPartnershipUnitOutstandingBasicAndDiluted	36482761	shares
CY2021	us-gaap	Weighted Average Number Of Limited Partnership And General Partnership Unit Outstanding Basic And Diluted WeightedAverageNumberOfLimitedPartnershipAndGeneralPartnershipUnitOutstandingBasicAndDiluted	11393753	shares
CY2022	us-gaap	Net Income Loss Per Outstanding Limited Partnership And General Partnership Unit Basic And Diluted NetIncomeLossPerOutstandingLimitedPartnershipAndGeneralPartnershipUnitBasicAndDiluted	-1.03
CY2021	us-gaap	Net Income Loss Per Outstanding Limited Partnership And General Partnership Unit Basic And Diluted NetIncomeLossPerOutstandingLimitedPartnershipAndGeneralPartnershipUnitBasicAndDiluted	-2.69
CY2022	jspr	Common Stock Warrants CommonStockWarrants	4999863	shares
CY2021	jspr	Common Stock Warrants CommonStockWarrants	4999883	shares
CY2022	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	6169180	shares
CY2021	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	2660383	shares
CY2022	jspr	Outstanding Rs Us OutstandingRSUs	2617445	shares
CY2022	jspr	Unvested Restricted Common Stock UnvestedRestrictedCommonStock	258847	shares
CY2021	jspr	Unvested Restricted Common Stock UnvestedRestrictedCommonStock	541225	shares
CY2022	jspr	Diluted Net Loss Per Share Attributable To Common Stockholders DilutedNetLossPerShareAttributableToCommonStockholders	14045335	shares
CY2021	jspr	Diluted Net Loss Per Share Attributable To Common Stockholders DilutedNetLossPerShareAttributableToCommonStockholders	8201491	shares
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-7914000	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-6433000	usd
CY2022Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	4518000	usd
CY2021Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	1729000	usd
CY2021Q4	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	735000	usd
CY2022	jspr	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	-1512000	usd
CY2021	jspr	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	-105000	usd
CY2022	jspr	Changes In Fair Value Of Earnout Liability ChangesInFairValueOfEarnoutLiability	-1202000	usd
CY2021	jspr	Changes In Fair Value Of Earnout Liability ChangesInFairValueOfEarnoutLiability	-1948000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	-108000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	633000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	1835000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	1095000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	16243000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	10095000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	846000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	-153000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	1281000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	510000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	484000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	407000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	20669000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	14683000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	3245000	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1410000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	985000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	222000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1090000	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	760000	usd
CY2022Q4	us-gaap	Deferred Costs And Other Assets DeferredCostsAndOtherAssets	351000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	99000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	6284000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities	13000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	34488000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	18005000	usd
CY2022Q4	us-gaap	Tax Credit Carryforward Valuation Allowance TaxCreditCarryforwardValuationAllowance	33925000	usd
CY2021Q4	us-gaap	Tax Credit Carryforward Valuation Allowance TaxCreditCarryforwardValuationAllowance	17682000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	563000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	323000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	563000	usd
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	302000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	21000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	563000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	323000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	16200000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10100000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	2700000	usd
CY2022	us-gaap	Interest Income Securities Taxable InterestIncomeSecuritiesTaxable	2200000	usd
CY2022Q4	jspr	Unrecognized Tax Benefit UnrecognizedTaxBenefit	828000	usd
CY2021Q4	jspr	Unrecognized Tax Benefit UnrecognizedTaxBenefit	252000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	894000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	576000	usd
CY2022Q4	jspr	Unrecognized Tax Benefits End Of Year UnrecognizedTaxBenefitsEndOfYear	1722000	usd
CY2021Q4	jspr	Unrecognized Tax Benefits End Of Year UnrecognizedTaxBenefitsEndOfYear	828000	usd
CY2022	jspr	Contribution Amount ContributionAmount	100000	usd
CY2021	jspr	Contribution Amount ContributionAmount	0	usd
CY2022	us-gaap	Defined Benefit Plan Significant Transactions Between Employer Or Related Parties And Plan During Year DefinedBenefitPlanSignificantTransactionsBetweenEmployerOrRelatedPartiesAndPlanDuringYear	The Company recorded $0.5 million for the founders’ advisory and consulting services performed for each of the years ended December 31, 2022 and 2021.
CY2022	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	0	usd
CY2021	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	36000	usd
CY2021Q4	us-gaap	Other Receivables OtherReceivables		usd
CY2022	jspr	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability		usd
CY2021	jspr	Issuance Of Series A1 Redeemable Convertible Preferred Stock For Cash IssuanceOfSeriesA1RedeemableConvertiblePreferredStockForCash		usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2022	jspr	Issuance Of Common Stock Upon Exercise Of Common Stock Warrants IssuanceOfCommonStockUponExerciseOfCommonStockWarrants		usd
CY2022	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities		usd
CY2022	us-gaap	Proceeds From Hedge Financing Activities ProceedsFromHedgeFinancingActivities		usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
CY2022	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock		usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2022	jspr	Conversion Of Redeemable Convertible Preferred Stock Into Common Stock In Connection With Reve ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithReve		usd
CY2022	jspr	Deferred Issuance Costs Reclassified To Additional Paid In Capital DeferredIssuanceCostsReclassifiedToAdditionalPaidInCapital		usd
CY2022	jspr	Net Liabilities Assumed Upon The Closing Of Reversed Recapitalization NetLiabilitiesAssumedUponTheClosingOfReversedRecapitalization		usd
CY2022	jspr	Recognition Of Earnout Liability RecognitionOfEarnoutLiability		usd
CY2022	jspr	Recognitionsettlement Of Derivatives Tranche Liability RecognitionsettlementOfDerivativesTrancheLiability		usd
CY2021	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit		usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent		usd
CY2021Q4	us-gaap	Other Liabilities And Deferred Revenue Noncurrent OtherLiabilitiesAndDeferredRevenueNoncurrent		usd
CY2021Q4	us-gaap	Capital Units Outstanding CapitalUnitsOutstanding		shares
CY2021Q4	jspr	Shares Available For Grant Under2019 Equity Incentive Plan SharesAvailableForGrantUnder2019EquityIncentivePlan		shares
CY2021	jspr	Outstanding Rs Us OutstandingRSUs		shares
CY2022Q4	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021Q4	us-gaap	Deferred Costs And Other Assets DeferredCostsAndOtherAssets		usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets		usd
CY2021Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory		usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities		usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001788028

Files In Submission

Name	View Source	Status
jspr-20221231_lab.xml	Edgar Link	unprocessable
0001213900-23-018542-index-headers.html	Edgar Link	pending
0001213900-23-018542-index.html	Edgar Link	pending
0001213900-23-018542.txt	Edgar Link	pending
0001213900-23-018542-xbrl.zip	Edgar Link	pending
f10k2022ex10-17_jaspertherap.htm	Edgar Link	pending
f10k2022ex23-1_jaspertherap.htm	Edgar Link	pending
f10k2022ex31-1_jaspertherap.htm	Edgar Link	pending
f10k2022ex31-2_jaspertherap.htm	Edgar Link	pending
f10k2022ex32-1_jaspertherap.htm	Edgar Link	pending
f10k2022ex4-3_jaspertherap.htm	Edgar Link	pending
f10k2022_jaspertherap.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
f10k2022_jaspertherap_htm.xml	Edgar Link	completed
jspr-20221231_cal.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
image_006.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
image_008.jpg	Edgar Link	pending
image_009.jpg	Edgar Link	pending
image_010.jpg	Edgar Link	pending
image_012.jpg	Edgar Link	pending
image_013.jpg	Edgar Link	pending
jspr-20221231.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
jspr-20221231_def.xml	Edgar Link	unprocessable
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
jspr-20221231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$JSPR
Jasper Therapeutics, Inc. Stock $jspr

2022 Q4 Form 10-K Financial Statement

#000121390023018542 Filed on March 08, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$JSPR Jasper Therapeutics, Inc. Stock $jspr

2022 Q4 Form 10-K Financial Statement

#000121390023018542 Filed on March 08, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$JSPR
Jasper Therapeutics, Inc. Stock $jspr